160 related articles for article (PubMed ID: 38030594)
21. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
22. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B.
Niu Q; Liu Z; Gao J; Wang Q
Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245
[TBL] [Abstract][Full Text] [Related]
23. Cisplatin-mediated down-regulation of miR-145 contributes to up-regulation of PD-L1 via the c-Myc transcription factor in cisplatin-resistant ovarian carcinoma cells.
Sheng Q; Zhang Y; Wang Z; Ding J; Song Y; Zhao W
Clin Exp Immunol; 2020 Apr; 200(1):45-52. PubMed ID: 31821542
[TBL] [Abstract][Full Text] [Related]
24. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.
Kinose Y; Sawada K; Nakamura K; Sawada I; Toda A; Nakatsuka E; Hashimoto K; Mabuchi S; Takahashi K; Kurachi H; Lengyel E; Kimura T
Oncotarget; 2015 May; 6(13):11342-56. PubMed ID: 25839163
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells.
Ma C; Huang T; Ding YC; Yu W; Wang Q; Meng B; Luo SX
Int J Clin Exp Pathol; 2015; 8(6):6533-9. PubMed ID: 26261532
[TBL] [Abstract][Full Text] [Related]
27. Expression of cancer stem cell markers CD24, EPHA1 and CD9 and their correlation with clinical outcome in epithelial ovarian tumours.
Nagare RP; Sneha S; Sidhanth C; Roopa S; Murhekar K; Shirley S; Swaminathan R; Sridevi V; Ganesan TS
Cancer Biomark; 2020; 28(3):397-408. PubMed ID: 32224528
[TBL] [Abstract][Full Text] [Related]
28. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
29. CD10
Ffrench B; Gasch C; Hokamp K; Spillane C; Blackshields G; Mahgoub TM; Bates M; Kehoe L; Mooney A; Doyle R; Doyle B; O'Donnell D; Gleeson N; Hennessy BT; Stordal B; O'Riain C; Lambkin H; O'Toole S; O'Leary JJ; Gallagher MF
Cell Death Dis; 2017 Oct; 8(10):e3128. PubMed ID: 29048400
[TBL] [Abstract][Full Text] [Related]
30. MiR-148a suppressed cell invasion and migration via targeting WNT10b and modulating β-catenin signaling in cisplatin-resistant colorectal cancer cells.
Shi L; Xi J; Xu X; Peng B; Zhang B
Biomed Pharmacother; 2019 Jan; 109():902-909. PubMed ID: 30551544
[TBL] [Abstract][Full Text] [Related]
31. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
32. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
[TBL] [Abstract][Full Text] [Related]
33. Neil 1 deficiency facilitates chemoresistance through upregulation of RAD18 expression in ovarian cancer stem cells.
Shukla D; Mandal T; Srivastava AK
Biochem Biophys Res Commun; 2024 Jun; 712-713():149907. PubMed ID: 38636303
[TBL] [Abstract][Full Text] [Related]
34. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
d'Adhemar CJ; Spillane CD; Gallagher MF; Bates M; Costello KM; Barry-O'Crowley J; Haley K; Kernan N; Murphy C; Smyth PC; O'Byrne K; Pennington S; Cooke AA; Ffrench B; Martin CM; O'Donnell D; Hennessy B; Stordal B; Finn S; McCann A; Gleeson N; D'Arcy T; Flood B; O'Neill LA; Sheils O; O'Toole S; O'Leary JJ
PLoS One; 2014; 9(6):e100816. PubMed ID: 24977712
[TBL] [Abstract][Full Text] [Related]
35. MicroRNA miR-30a inhibits cisplatin resistance in ovarian cancer cells through autophagy.
Cai Y; An B; Yao D; Zhou H; Zhu J
Bioengineered; 2021 Dec; 12(2):10713-10722. PubMed ID: 34747309
[TBL] [Abstract][Full Text] [Related]
36. miR-613 inhibits liver cancer stem cell expansion by regulating SOX9 pathway.
Li B; Liu D; Yang P; Li HY; Wang D
Gene; 2019 Jul; 707():78-85. PubMed ID: 31075412
[TBL] [Abstract][Full Text] [Related]
37. miR-29c-3p inhibits autophagy and cisplatin resistance in ovarian cancer by regulating FOXP1/ATG14 pathway.
Hu Z; Cai M; Zhang Y; Tao L; Guo R
Cell Cycle; 2020 Jan; 19(2):193-206. PubMed ID: 31885310
[TBL] [Abstract][Full Text] [Related]
38. Enhanced expression of DNA polymerase eta contributes to cisplatin resistance of ovarian cancer stem cells.
Srivastava AK; Han C; Zhao R; Cui T; Dai Y; Mao C; Zhao W; Zhang X; Yu J; Wang QE
Proc Natl Acad Sci U S A; 2015 Apr; 112(14):4411-6. PubMed ID: 25831546
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
[TBL] [Abstract][Full Text] [Related]
40. miR-509-3p enhances platinum drug sensitivity in ovarian cancer.
Niu L; Ni H; Hou Y; Du Q; Li H
Gene; 2019 Feb; 686():63-67. PubMed ID: 30408550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
